EGF prevented the meshwork disruption seen in previous trials, therefore, EGF was, then, included in an AD mouse in vivo model where the EGF treatment was shown to reduce the AD-induced angiogenic changes, such as meshwork disruption [147]. The gene discussed is EGF; the disease is Alzheimer disease.